SSanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Work here?Claim your company
Industries
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$9.4B
Above
Industry Average
Funded Over
8 Rounds
Windward Bio Group AG, a clinical-stage biotechnology company based in Basel, Switzerland, priced its initial public offering (IPO) of 10,294,117 common shares at $17 per share. Underwriters have a 30-day option to buy up to 1,544,117 more shares at the IPO price. Sanofi Foreign Participations B.V. will buy $50 million of shares and pre-funded warrants in a concurrent private placement, also at the IPO price. Combined gross proceeds are expected to reach $225 million, before discounts, commissions, and expenses. Shares were expected to begin trading on the Nasdaq Global Select Market on November 13, 2026, under the ticker WWB. The offering is expected to close on November 16, 2026, and the private placement depends on the IPO closing. Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank are joint book-running managers.
BNP Paribas upgraded Sanofi to Outperform from Neutral on Monday, November 9. The analyst rating helped the drugmaker rank eighth on a list of stocks analysts just upgraded, with average upside potential of 8%. Bulls point to growth in Dupixent, a widening product base, and rising profit through 2030. Dupixent, its treatment for eczema, asthma, and other inflammatory conditions, sold €5.7 billion in the third quarter, up 34.8%. Advanced therapies reach only about 20% of eczema patients, which leaves room to grow. Sanofi raised its 2026 outlook, and its finance chief expects operating profit to rise every year through 2030. Planning for Dupixent's eventual patent loss is management's top priority, and Sanofi has expanded its alliance with Regeneron to develop next-generation antibodies. Bears cite falling vaccine sales, a slightly negative price effect expected in 2027, and the discontinuation of two experimental drugs. Divestments will also cut 2027 sales by about €1.3 billion.
Shares of Nurix Therapeutics (NRIX) fell 35% after hours on Tuesday, after partner Sanofi ended development of SAR448272, an experimental oral drug it licensed from Nurix. Sanofi is terminating the early-stage first-in-human trial. The compound was being studied for type 2 inflammatory and autoimmune conditions such as atopic dermatitis and asthma. The decision ends roughly $455 million in potential milestone payments, plus royalties, tied to the program. Nurix has received about $139 million from Sanofi under their 2019 deal, including $10 million when the trial began this year. Nurix said its cash runway guidance is unchanged. It held $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, which it expects will fund operations into the second half of 2029.
Sanofi shares jumped nearly 6% on Friday after the drugmaker raised its 2026 outlook and said it is open to larger deals. The company now expects sales to grow in the low teens this year, with business earnings per share up in the mid-teens at constant exchange rates. Third-quarter sales rose 14.3% to 14.44 billion, and operating income was 5.43 billion. Dupixent remained the main growth driver, with sales up 34.8% to 5.7 billion. New medicines added 1.4 billion. Chief financial officer Francois Roger said Sanofi could consider deals above its typical $2 billion to $5 billion range. The company continues to focus on immunology, rare diseases, and vaccines.
Sanofi reported third-quarter sales of €14.4 billion, up 14.3% at constant exchange rates, and raised its 2026 outlook. Business operating income rose 19.7%, while business EPS increased 19.6%. The company now expects 2026 sales growth of 13% to 15% and business EPS growth of 15% to 17%. Dupixent sales hit €5.7 billion, with more than 1.5 million patients treated worldwide. Sanofi still targets Dupixent sales of €25 billion by 2030. Sanofi is focusing on immunology, rare diseases, and vaccines. It discontinued two development programmes and expanded its Regeneron alliance to four next-generation antibodies. Planned divestments are expected to cut 2027 sales by about €1.3 billion.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs